CDA Antibody

中文名稱：

CDA兔多克隆抗體
貨號：

CSB-PA00845A0Rb
規格：

￥440
圖片：
Western blot
All lanes: CDA antibody at 2µg/ml + 293T whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 17 kDa
Observed band size: 17 kDa

Immunohistochemistry of paraffin-embedded human spleen tissue using CSB-PA00845A0Rb at dilution of 1:100

Immunofluorescent analysis of Hela cells using CSB-PA00845A0Rb at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

Immunohistochemistry of paraffin-embedded human liver tissue using CSB-PA00845A0Rb at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) CDA Polyclonal antibody
Uniprot No.：

P32320
基因名：

CDA
別名：

CDA antibody; CDDCytidine deaminase antibody; EC 3.5.4.5 antibody; Cytidine aminohydrolase antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Cytidine deaminase protein (1-146AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，CDA Antibody (CSB-PA00845A0Rb)，的標記方式是Non-conjugated。對于CDA Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA00845B0Rb	CDA Antibody, HRP conjugated	ELISA
FITC	CSB-PA00845C0Rb	CDA Antibody, FITC conjugated
Biotin	CSB-PA00845D0Rb	CDA Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
基因功能參考文獻：
1. SNPs in CDA and CES2 were associated with benefit from the addition of capecitabine to chemotherapy in metastatic breast cancer patients PMID: 28827188
2. The observed incomplete sister chromatid disjunction may be due to the accumulation of unreplicated DNA during mitosis in CDA-deficient cells, as reflected in the changes in centromeric DNA structure associated with the decrease in basal PARP-1 activity. PMID: 28463527
3. Intracerebral microdialysis revealed that clonal NSC line to stably express cytosine deaminase (CD-NSCs) produced 5-FU locally in the brain in a 5-FC dose-dependent manner. Collectively, our results from this first-in-human study demonstrate initial safety and proof of concept regarding the ability of NSCs to target brain tumors and locally produce chemotherapy. PMID: 27979915
4. results indicate that rs2072671 in CDA may be an important prognostic marker in NK-AML patients. PMID: 26354033
5. tumor cell lines that are susceptible to epigenetic nucleosides overexpress cytidine deaminase (CDA); CDA converts 5hmdC and 5fdC into variants of uridine that are incorporated into DNA, resulting in accumulation of DNA damage, and ultimately, cell death PMID: 26200337
6. RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
7. stimulation of PARP-1 activity in CDA-deficient cells restores replication and, thus, chromosome segregation. Moreover, increasing intracellular dCTP levels generates under-replication-induced sister-chromatid bridges as efficiently as PARP-1 knockdown PMID: 26181065
8. n the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death PMID: 26090398
9. Single nucleotide polymorphisms in cytidine deaminase gene were associated with the efficacy of gemcitabine in Biliary Tract Cancer. PMID: 26418006
10. Polymorphisms in ABCB1, CDA, ENOSF1,and TYMS could help to predict specific and overall severe adverse reactions to capecitabine. PMID: 25691056
11. miR-484-modulated cytidine deaminase has a dual impact in promoting chemoresistance and suppressing cell proliferation in breast cancer PMID: 25643696
12. This case report calls for further prospective studies investigating the exact role that CDA status plays in the clinical outcome of patients treated with azacytidine. PMID: 25850965
13. The A79C CDA polymorphism did not show a significant impact on the response rate to gemcitabine in NSCLC patients, while the wild type CDA genotype was indeed correlated to a lower rate of incidence of severe anemia in patients taking gemcitabine. PMID: 24557790
14. These results suggest that CDA 79A>C polymorphisms is a potential biomarker for toxicity of gemcitabine-based chemotherapy and a CDA testing before gemcitabine administration is preferred. PMID: 25582275
15. These results provide suggestive evidence of a favorable effect for the XPD 312Asp/Asp and XPD 751Lys/Lys genotypes with respect to overall survival rates in platinum-treated NSCLC patients PMID: 24841663
16. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. PMID: 23995783
17. The T70 variant has a lower catalytic efficiency toward the analyzed substrates when compared to the A70 variant, suggesting that patients carrying the 208G>A SNP may have a greater exposure to cytosine based pro drugs PMID: 24183806
18. Carriers of the CDA*2B haplotype displayed higher CDA activity. PMID: 23651026
19. ultrarapid metabolizer patients are nearly five-times more likely to have progressive disease than patients with normal or low CDA activities. PMID: 23837479
20. Studied human CDA using site-directed mutagenesis: through these studies it was possible to understand the role exerted by specific amino acid residues in CDA active site and in the contacts between subunits. PMID: 23033855
21. Variation in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. PMID: 23736036
22. Data indicate cytidine deaminase rapid expression upon doxycycline application in mouse haematopoietic system. PMID: 22592598
23. In conclusion, in this prospective randomized adjuvant study of patients with pancreatic cancer, the cytidine deaminase polymorphism is validated as a predictive marker of gemcitabine hematological toxicity, but not with treatment response or survival PMID: 21625252
24. It is evident that the DCK and CDA polymorphisms might be the important markers for the AML patients' therapy outcomes in a Chinese population. PMID: 22884143
25. Chinese patients carrying A79C variant C allele of CDA were found to be at higher risk of developing severe neutropenia after gemcitabine-based chemotherapy. PMID: 22546611
26. CDA RNA expression as well as Ara-C IC showed wide variation in AML samples and normal controls. PMID: 22304580
27. cytidine deaminase enzymatic activity appears to be the strongest candidate biomarker of activity and efficacy of platinum-gemcitabine-based chemotherapy in advanced non-small-cell lung cancer patients PMID: 21652582
28. Cytidine deaminase (CDA) 435 T/T genotype was significantly associated with better response to treatment and the CDA 435 C/T genotype was associated with a significantly increased risk of nonhematological toxicity. PMID: 22052224
29. Data show that the CDA/DCK ratio was 3 fold higher in non-responders than responders (P<.05), suggesting that this could be a mechanism of primary resistance. PMID: 21858090
30. Aberrant activation-induced cytidine deaminase expression is correlated with persistent inflammatory condition induced by H. pylori infection and may contribute to the development of gastric cancer through an inflammatory condition and intestinalization. PMID: 21538122
31. the deleted allele of rs3215400 in the promoter of cytidine deaminase shows an increased allele-specific expression and is significantly associated with an increased risk of capecitabine-induced hand-foot syndrome PMID: 21325291
32. Single nucleotide polymorphisms in cytidine deaminase is associated with the pharmacological advantage of prolonged dose rate gemcitabine. PMID: 21332653
33. Compared with their parental cells, the expressions of CDA, RRM1, PTEN and ERCC1 increase in human gemcitabine-resistant non-small cell lung cancer cell lines. PMID: 20211060
34. These investigations reinforced the hypothesis that in human CDA the side chain of Y33 is involved in intersubunit interactions with four glutamate residues forming a double latch that connects each of the two pairs of monomers of the tetrameric CDA. PMID: 20637228
35. The aim of this study was also to assess the distribution of genotypic variants of CDA in a central Italy population. PMID: 19941076
36. The cytidine deaminase 208A genotype is shown to be more sensitive to cytosine arabinoside than the 208G genotype in childhood acute leukemia. PMID: 19035178
37. Activation-induced cytidine deaminase expression suggests diffuse large B-cell lymphoma may arise from a putative interfollicular large B cell. PMID: 20196672
38. Curcumin downregulated Helicobacter pylori induced cytidine deaminase expression in gastric epithelial cells. PMID: 19889077
39. serum adenosine deaminase and cytidine deaminase levels were significantly higher in systemic lupus erythematosus patients PMID: 12113294
40. This enzyme can act on deoxycytidine in single-stranded DNA, but requires the action of RNase A. PMID: 12651944
41. The level of CDD mRNA expression varies at the different stage of acute leukemia. The expression level of CDD seems not to be a prognostic factor. PMID: 12844405
42. Intersubunit interactions in human cytidine deaminase using wild and recombinant, amino acid-substituted enzymes PMID: 14565460
43. Understanding the catalytic mechanism by crystallization of the E. coli homolog PMID: 14565461
44. Presence of several GATA1 binding sites in the CDAsf promoter and the uniform detection of GATA1 mutations in DS megakaryocytic leukemia suggested the potential role of GATA1 in regulating CDA transcription. PMID: 14744791
45. analysis of isoenzymatic forms of human cytidine deaminase PMID: 15713780
46. Molecular model of cytidine deaminase. PMID: 16303324
47. Gene transfer increased the resistance of CDD-transduced cord blood and peripheral blood-derived progenitor cells for 20-100 nM cytarabine and 8-10 nM gemcitabine. Protection was observed for progenitors of erythroid as well as myeloid differentiation. PMID: 16304576
48. 6 SNPs ( -92A>G, -205C>G, -451C>T, -897C>A, -1075A>G and -1181G>A) in promoter of CDA may influence Ara-C chemosensitivity. PMID: 16446974
49. Described the identification and characterization of HSCD, which is the product of alternative splicing of the HCD gene PMID: 17464349
50. After gene trasfer of CDA, this enzyme plus 5-fluorocytosine with TRAIL may be useful for the therapy of tumors resistant to TRAIL. PMID: 17479107
顯示更多

收起更多
蛋白家族：

Cytidine and deoxycytidylate deaminase family
組織特異性：

Highly expressed in granulocytes while expression is very low in fibroblasts, chondrocytes, monocytes, and T- as well as B-cell lines.
數據庫鏈接：

HGNC: 1712

OMIM: 123920

KEGG: hsa:978

STRING: 9606.ENSP00000364212

UniGene: Hs.466910

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
VCP Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, IP

Species Reactivity: Human, Rat
USP7 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
USP24 Recombinant Monoclonal Antibody

Applications: ELISA, IF, FC

Species Reactivity: Human